- Trials with a EudraCT protocol (55)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (21)
55 result(s) found for: Short stature.
Displaying page 1 of 3.
EudraCT Number: 2009-012089-30 | Sponsor Protocol Number: UZB-PED-2009-001 | Start Date*: 2010-03-19 | |||||||||||
Sponsor Name:UZ Brussel | |||||||||||||
Full Title: Frequency and mechanisms of resistance to IGF-1 generation in non-GH deficient short children with low IGF-1 concentration | |||||||||||||
Medical condition: Prepubertal children with stature < -2 SDS, IGF-1 < the lowest reference limit and normal growth hormone response to an ITT or glucagon test | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000584-85 | Sponsor Protocol Number: SGA_Metformin | Start Date*: 2018-11-21 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Effect of insulin sensitization on insulin like growth factor-1 responses to growth hormone treatment in children born small for gestational age | |||||||||||||
Medical condition: Growth disorder in children born small for gestational age | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001750-25 | Sponsor Protocol Number: B9R-FP-GDGI | Start Date*: 2007-03-22 | |||||||||||
Sponsor Name:LILLY FRANCE | |||||||||||||
Full Title: Efficacy and Safety of Somatropin in Combination with Leuprorelin Compared to Somatropin Alone and to an Untreated Control Group in Pubertal Children with Idiopathic Short Stature | |||||||||||||
Medical condition: Children with Idiopathic Short Stature (ISS) at puberty onset. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000843-29 | Sponsor Protocol Number: MS316 | Start Date*: 2019-05-31 |
Sponsor Name:Ipsen Pharma | ||
Full Title: Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) Combination Therapy in Children with Short Stature Associated with IGF-1 Deficiency: A Six-year,... | ||
Medical condition: Idiopatic Short Stature in prepubertal children associated with low IGF-1 and normal stimulated GH response | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-002613-30 | Sponsor Protocol Number: GH-3899 | Start Date*: 2016-04-25 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 12-month, open-labelled, randomised, parallel-group, multi-centre, interventional trial to evaluate the efficacy and safety of recombinant human growth hormone (hGH) (Norditropin® Nordilet®) ther... | |||||||||||||
Medical condition: Idiopathic short stature | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005607-13 | Sponsor Protocol Number: NN8640-4467 | Start Date*: 2022-07-15 | ||||||||||||||||||||||||||
Sponsor Name:NOVO NORDISK. S.P.A. | ||||||||||||||||||||||||||||
Full Title: A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with ... | ||||||||||||||||||||||||||||
Medical condition: Short stature born small for gestational age Turner syndrome Noonan syndrome Idiopathic short stature | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) SI (Trial now transitioned) IE (Completed) DE (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003247-70 | Sponsor Protocol Number: UZAPED1 | Start Date*: 2007-10-29 | |||||||||||
Sponsor Name:Belgian Study Group for Pediatric Endocrinology | |||||||||||||
Full Title: Efficacy and safety of a 4 year combination therapy of growth hormone and gonadotropin- releasing hormone agonist in children with a short predicted height. | |||||||||||||
Medical condition: predicted short stature | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004172-32 | Sponsor Protocol Number: A6281280 | Start Date*: 2015-04-01 |
Sponsor Name:Pfixer Inc | ||
Full Title: A Four-Year Open-Label Multi-Center Randomized Two-Arm Study of Genotropin in Idiopathic Short Stature Subjects: Comparing an Individualized, Target-Driven Treatment Regimen to Standard Dosing of G... | ||
Medical condition: Idiopathic short stature (ISS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2006-001721-26 | Sponsor Protocol Number: B9R-EW-GDFC(a) | Start Date*: 2006-09-25 |
Sponsor Name:UAB “Eli Lilly Lietuva” | ||
Full Title: The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) | ||
Medical condition: Short Stature | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: LT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001095-11 | Sponsor Protocol Number: MS308 | Start Date*: 2019-05-31 |
Sponsor Name:Ipsen Pharma | ||
Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF SHORT STATURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A MULTICENTER, OPEN-LABEL, CONCENTRATION-CONTROLLED TRIAL | ||
Medical condition: Children with growth failure associated with primary insulin-like growth factor deficiency (IGFD). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-000432-26 | Sponsor Protocol Number: versie1,dd01-02-2012 | Start Date*: 2012-09-26 |
Sponsor Name:Maastricht University Medical Centre | ||
Full Title: Prospective study on the metabolic and linear growth effects of growh hormone treatment in children with Kabuki Syndrome | ||
Medical condition: Kabuki Syndrome (KS, OMIM 147920) with a mutation in MLL2 gene. | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000750-22 | Sponsor Protocol Number: GHLIQUID-4020 | Start Date*: 2018-04-12 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A trial investigating the long-term efficacy and safety of two doses of NN-220 (somatropin [genetical recombination]) in short stature due to Noonan syndrome | |||||||||||||
Medical condition: Noonan Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000232-10 | Sponsor Protocol Number: NN8640-4245 | Start Date*: 2019-05-15 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin® in children with short stature born small for gestational age with no ca... | |||||||||||||
Medical condition: Short stature in children born small for gestational age with no catch-up growth by 2 years of age or older | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) NO (Ongoing) IE (Completed) EE (Completed) HU (Trial now transitioned) LV (Trial now transitioned) PL (Completed) ES (Prematurely Ended) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019980-13 | Sponsor Protocol Number: A-95-58035-017 | Start Date*: 2012-05-14 | |||||||||||
Sponsor Name:Ipsen Farmaceutica b.v. | |||||||||||||
Full Title: Predictive value of baseline and stimulated serum IGF-I and IGFBP-3 during a dose-escalation IGF-I generation test with NutropinAq for the 1 year growth response to growth hormone (GH) therapy in s... | |||||||||||||
Medical condition: Severe idiopathic short stature | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003100-39 | Sponsor Protocol Number: NSGA | Start Date*: 2013-11-28 | |||||||||||
Sponsor Name:Dutch Growth Research Foundation | |||||||||||||
Full Title: Standardized versus individualized growth hormone treatment of short children born small for gestational age: Effects on short-term and longterm efficacy, long-term psychosocial development, gluc... | |||||||||||||
Medical condition: Children who are born small for gestational age, defined as a birth length and/or birth weight < -2 SD score, who fail to show catch-up growth (short stature). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000914-47 | Sponsor Protocol Number: GHLIQUID-1517 | Start Date*: 2017-05-23 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A long-term, multi-centre, randomised, controlled, double-blind, parallel-group trial, investigating the efficacy and safety of two doses of NN-220 in subjects with short stature born small for ges... | |||||||||||||
Medical condition: Foetal growth problem Small for Gestational Age Growth hormone deficiency in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001507-19 | Sponsor Protocol Number: 04/5/025 | Start Date*: 2005-05-22 |
Sponsor Name:National Children's Hospital & Trinity College Dublin | ||
Full Title: Treatment with recombinant Growth Hormone in Children born Small for Gestational Age (SGA) without Catch-up Growth. | ||
Medical condition: Short stature in children born small for gestational age without catch up growth | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004781-33 | Sponsor Protocol Number: A6281273 | Start Date*: 2005-07-13 |
Sponsor Name:Pfizer Pharma GmbH | ||
Full Title: Somatropin Therapy for Short Children Born of Premature Gestation: A Controlled, Prospective Randomized, Multicenter Study with an Untreated Control Group | ||
Medical condition: Short children born of premature gestation | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002684-25 | Sponsor Protocol Number: BSGPE2 | Start Date*: 2012-08-06 | |||||||||||
Sponsor Name:Antwerp University Hospital | |||||||||||||
Full Title: Efficacy and safety of a 4 year pubertal therapy with growth hormone (somatropine Omnitrope) or an aromatase inhibitor (letrozole Femara) or the combination of both in boys with a short predicted h... | |||||||||||||
Medical condition: boys with idiopathic short adult stature defined as a predicted adult height below or equal to 164.0 cm ( -2.5 SDS) without a known cause | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004104-30 | Sponsor Protocol Number: 307-MET-9002-0009 | Start Date*: 2015-04-01 |
Sponsor Name:Pharmacia & Upjohn S.A. | ||
Full Title: Treatment With Recombinant Human Growth Hormone (Genotonorm) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety | ||
Medical condition: Juvenile idiopathic arthritis (JIA) and nephrotic syndrome (NeS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
